Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.

H Corominas, I Castellví, V Pomar, R Antonijoan, I Mur, L Matas, I Gich, N de Benito, A Laiz, D Castillo, L Villamarin, D Filella, AM Millán, María Ángeles Quijada, Mireia Puig-Campmany, P Domingo, Jordi Casademont

Producción científica: Contribución a una revistaArtículoInvestigaciónrevisión exhaustiva

13 Citas (Scopus)

Resumen

Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with COVID-19 treated with TCZ had a lower mortality rate (5·8%) compared with the regional mortality rate (11%), hospitalized patient's mortality (10%), and slightly lower than hospitalized patients treated with our standard of care alone (6%). We found that TCZ rapidly decreased acute phase reactants, ferritin and liver release of proteins. D-Dimer decreased slowly. We did not observe specific safety concerns. Early administration of IL6-R antagonists in COVID-19 patients with impending hyperinflammatory response, may be safe and effective treatment to prevent, ICU admission and further complications.
Idioma originalInglés
Número de artículo108631
Número de páginas7
PublicaciónClinical immunology (Orlando, Fla.)
Volumen223
DOI
EstadoPublicada - feb 2021

Huella

Profundice en los temas de investigación de 'Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.'. En conjunto forman una huella única.

Citar esto